For your morning coffee: enjoy our latest newsletter. https://lnkd.in/eNp3SrNm Subscribe and be the first to know: https://lnkd.in/epdwcpnu
V-Bio Ventures
Venture Capital and Private Equity Principals
Sint-Denijs-Westrem (Gent), Flanders 3,140 followers
We empower life sciences innovation by finding, building and financing European start-ups and early-stage companies.
About us
V-Bio Ventures is a venture capital fund that finds, builds and finances young, innovative companies in the life sciences arena. Our fund works closely with Belgium-based VIB, one of the world’s premier life science institutes. We invest throughout Europe in start-up and early-stage companies with high growth potential. We focus on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.
- Website
-
http://www.v-bio.ventures
External link for V-Bio Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Sint-Denijs-Westrem (Gent), Flanders
- Type
- Partnership
- Founded
- 2015
Locations
-
Primary
Pieter van Reysschootlaan 2
104
Sint-Denijs-Westrem (Gent), Flanders 9051, BE
Employees at V-Bio Ventures
Updates
-
A Topx Network event is always an excellent opportunity to discuss best practises - Join this event hosted by anacura on october 23rd to listen to our managing partner Christina Takke as she joins a panel discussion on "The Strengh of Feminine Leadership" Registration: https://lnkd.in/e2PzdSGu #femaletechleaders #womenintech #womeninbusiness #venturecapital
We are very excited about the first stand-alone TOPX Network event in Belgium, hosted by anacura on 23 October! This marks a significant milestone for our network, and we couldn't be more enthusiastic to bring this impactful event to Belgium. With the theme of "The Strength of Feminine Leadership: Turning Challenges into Empowering Opportunities", this network session is designed to celebrate and explore the positive attributes associated with feminine leadership. Moving beyond the often-discussed barriers, we will delve into the strengths that feminine leadership brings to the table, such as emotional intelligence, collaboration, and intuition. We have an incredible lineup of speakers, including Hilde Windels - Board Member at a.o. Gimv, MDxHealth & Celyad, Christina Takke - Managing Director, VBio Ventures, Dana Krueger - Global Leadership Advisor, Russell Reynolds Associates. This insightful panel discussion will be moderated by our TOPX Network member Kim Heylen - Managing Director, Labo Nuytinck. This is a unique opportunity to gain insights from some of the most influential leaders in the industry and network with like-minded professionals. Don't miss out on this chance to be part of an inspiring conversation! Register now to secure your spot: https://lnkd.in/ekx-XH5b Let's come together to celebrate and empower feminine leadership! See you there!
-
V-Bio Ventures reposted this
We had a great discussion with Brad Loncar @ Coave Therapeutics facilities, providing insight into our Advanced Vector Ligand Conjugates technology . Thanks Brad for stopping by!
𝐅𝐫𝐨𝐦 𝐏𝐚𝐫𝐢𝐬: Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest. CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector manufacturing. Plus, he shares an update on the company's fundraising, partnering, and wholly owned programs. Full video: https://lnkd.in/gbxpdeze BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Catch our Partner Ward Capoen at LSX Nordic Congress next month who will join fellow investors for a panel discussion on "Northern Horizons: Navigating the Nordic Biotech Investment Frontier in 2024 and Beyond". Looking forward to networking and exploring opportunities together.
📣 Northern Horizons: Navigating the Nordic Biotech Investment Frontier in 2024 and Beyond Join our panel of Biotech Leaders as they discuss: · How the Nordic biotech ecosystem has demonstrated success in the face of global challenges - Factors contributing to stability - The latest trends and cutting-edge technologies driving biotech advancements in the Nordic region, and discussing their implications for investors and startups - Shifting investment strategies in an evolving regulatory environment, and attracting and retaining investment in Nordic biotech 🎙 Hear from: · Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners · Jeroen Bakker, Partner, Novo Holdings · Ingrid Teigland Akay, Managing Partner, Hadean Ventures · Ward Capoen, Partner, V-Bio Ventures · Claudio Costa-Neto, CSO, JEITO Find out more: https://lnkd.in/g99PBfeK #LSXNordic #Biotech
-
V-Bio Ventures reposted this
We are thrilled to welcome Carl Bjartmar, M.D., Ph.D., as our new Chief Medical Officer! In combination with a successful track record in advancing innovative therapeutic programs for rare diseases within major pharma and biotech organizations, Dr. Bjartmar’s deep expertise in clinical research will support our mission of developing our next-generation, Best-in-Class HDAC6 inhibitors as potential treatments for peripheral and CNS diseases. To learn more about Dr. Bjartmar, read here: https://lnkd.in/eU97wG_e #newappointment #biotech #team #healthcare #innovation #pharma #drugdevelopment
-
🤝 VC and founders work closely together and need to have a strong trusting relationship to get the most out of this partnership and ensure success - read the thoughts of Charles Margarit, PhD in V-Bio Ventures' latest contribution to the BioVox newsletter. https://lnkd.in/ekt29rtj #VentureCapital #Innovation #entrepreneurship #founder #ondernemen
-
Wonderful news to start the day! V-Bio Ventures portfolio company Confo Therapeutics announces its € 60 million Series B to continue building a GPCR powerhouse focused on rare and metabolic diseases. A warm welcome to the new investors.
-
📢 Our portfolio company Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors announces a partnership with Orchestra Life Sciences to enhance the availability and application of Pb-212, a promising radioisotope for targeted alpha therapy (TAT) for cancer treatment. full press release: https://lnkd.in/epF2AENt #LifeScienceVC #LifeSciences #VentureCapital #Innovation #Biotechnology #oncology #cancercare #cancer #radiopharmaceuticals #cancertreatment #oncologyresearch #RT #radiotherapy #radiationoncology
Exciting News at Precirix! We are partnering with Orchestra Life Sciences to enhance the availability and application of Pb-212, a promising radioisotope in the field of targeted alpha therapy (TAT) for cancer treatment. Click the link below for the full press release: https://lnkd.in/gD3ChkDw
-
📢 Our portfolio company Protealis, a pioneer in the breeding of high yield, high protein soy varieties adapted to Northern Europe, has appointed Frank van Lierde as independent member of its board of directors. His extensive experience in the food and bio-industrial sectors brings invaluable expertise to Protealis as the company expands its commercial footprint Welcome on board Frank van Lierde! Press release here: https://lnkd.in/eS_Da48i #biotech #agribusiness #Sustainability #agriculture #shapingthefuture
🗞️ Press news: @Frank van Lierde Joins Protealis’ Board of Directors 👉 https://lnkd.in/eXeyECev #TeamProtealis #NewBoardMember #Commercialization #SustainableSoy
-
Exciting news from our portfolio company Augustine. Congrats to the entire team!
Wonderful start of the day: our portfolio company Augustine Therapeutics announces the first closing of its Series A, welcoming Asabys Partners and Eli Lilly and Company as new investors. And congratulations Gerhard Koenig for becoming executive chairman.